hydroxyurea has been researched along with HIV in 12 studies
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 9.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "A 1993 presentation described the role of hydroxyurea in inhibiting HIV replication in peripheral blood mononuclear cells and macrophages as well as a synergistic effect with ddI." | 9.08 | Hydroxyurea in HIV therapy. ( , 1998) |
| " and Europe supports the effect of the anticancer drug hydroxyurea against HIV-1, and its potential synergistic effect with ddl." | 7.69 | Hydroxyurea, a potential new anti-HIV agent. ( Torres, G, 1995) |
| "Hydroxyurea was not found to be beneficial when used in association with STIs in patients during PHI." | 6.72 | The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). ( Bloch, MT; Carr, A; Cooper, DA; Finlayson, RJ; Grey, P; Irvine, K; Kaldor, JM; Kelleher, AD; Law, M; McFarlane, R; Petoumenos, K; Quan, D; Smith, DE; Zaunders, JJ, 2006) |
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 5.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "A 1993 presentation described the role of hydroxyurea in inhibiting HIV replication in peripheral blood mononuclear cells and macrophages as well as a synergistic effect with ddI." | 5.08 | Hydroxyurea in HIV therapy. ( , 1998) |
| "Hydroxyurea obstructs HIV from reproducing, is effective when combined with nucleoside analogue reverse transcriptase inhibitors, and it is difficult for HIV to develop a resistance to it." | 3.70 | Hydroxyurea - new observations. ( , 1998) |
| " and Europe supports the effect of the anticancer drug hydroxyurea against HIV-1, and its potential synergistic effect with ddl." | 3.69 | Hydroxyurea, a potential new anti-HIV agent. ( Torres, G, 1995) |
| "Hydroxyurea was not found to be beneficial when used in association with STIs in patients during PHI." | 2.72 | The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). ( Bloch, MT; Carr, A; Cooper, DA; Finlayson, RJ; Grey, P; Irvine, K; Kaldor, JM; Kelleher, AD; Law, M; McFarlane, R; Petoumenos, K; Quan, D; Smith, DE; Zaunders, JJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shirlaw, PJ | 1 |
| Chikte, U | 1 |
| MacPhail, L | 1 |
| Schmidt-Westhausen, A | 1 |
| Croser, D | 1 |
| Reichart, P | 1 |
| de Mendoza, C | 1 |
| Paxinos, E | 1 |
| Barreiro, P | 1 |
| Camino, N | 1 |
| Núñez, M | 1 |
| Soriano, V | 1 |
| Lori, F | 2 |
| Pollard, RB | 1 |
| Whitman, L | 1 |
| Bakare, N | 1 |
| Blick, G | 1 |
| Shalit, P | 1 |
| Foli, A | 1 |
| Peterson, D | 1 |
| Tennenberg, A | 1 |
| Schrader, S | 1 |
| Rashbaum, B | 1 |
| Farthing, C | 1 |
| Herman, D | 1 |
| Norris, D | 1 |
| Greiger, P | 1 |
| Frank, I | 1 |
| Groff, A | 1 |
| Lova, L | 1 |
| Asmuth, D | 1 |
| Lisziewicz, J | 1 |
| Bloch, MT | 1 |
| Smith, DE | 1 |
| Quan, D | 1 |
| Kaldor, JM | 1 |
| Zaunders, JJ | 1 |
| Petoumenos, K | 1 |
| Irvine, K | 1 |
| Law, M | 1 |
| Grey, P | 1 |
| Finlayson, RJ | 1 |
| McFarlane, R | 1 |
| Kelleher, AD | 1 |
| Carr, A | 1 |
| Cooper, DA | 1 |
| Ahluwalia, GS | 1 |
| Gao, WY | 1 |
| Mitsuya, H | 1 |
| Johns, DG | 1 |
| Cohen, J | 1 |
| Szekeres, T | 1 |
| Fritzer-Szekeres, M | 1 |
| Elford, HL | 1 |
| Mascolini, M | 1 |
| Torres, G | 1 |
3 reviews available for hydroxyurea and HIV
| Article | Year |
|---|---|
Oral and dental care and treatment protocols for the management of HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotic Prophylaxis; Antiretroviral Thera | 2002 |
The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
Topics: Antineoplastic Agents; Antiviral Agents; Enzyme Inhibitors; HIV; Humans; Hydroxamic Acids; Hydroxyur | 1997 |
Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Nucleic Acid S | 1999 |
3 trials available for hydroxyurea and HIV
| Article | Year |
|---|---|
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Drug-Re | 2005 |
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combinatio | 2006 |
Hydroxyurea in HIV therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; H | 1998 |
6 other studies available for hydroxyurea and HIV
| Article | Year |
|---|---|
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; | 2004 |
2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.
Topics: Amides; Biotransformation; Biphenyl Compounds; Cell Line; Deoxyguanosine; Floxuridine; HIV; HIV Reve | 1996 |
HIV suppressed long after treatment.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Hepatitis A; HIV; HIV Infections; Humans; Hydroxy | 1997 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug S | 1995 |
Hydroxyurea - new observations.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinati | 1998 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Le | 1995 |